Ambroxol is indicated for:
Irrespective of gender only Children (1 year - 12 years old)
Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old) , Adults (18 - 65 years old)
Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Ambroxol is contraindicated in the following cases:
Ambroxol should not be given concomitantly with antitussives or with drugs that have an atropic effect.
Ambroxol crosses into the breast milk in animals. As there is no adequate experience in humans to date, ambroxol should only be used in lactation after careful benefit/risk assessment.
There are no sufficient data for the use of ambroxol in pregnant women. This particularly concerns the period up to the 28th week of pregnancy. Ambroxol has shown no teratogenic effects in animal-experiment studies. Ambroxol should only be used in pregnancy after careful benefit/risk evaluation, particularly during the first trimester.